Vipivotide tetraxetan (PSMA-617) is a radiotheranostic agent featuring a glutamate-urea-lysine pharmacophore for selective prostate-specific membrane antigen binding, a flexible linker, and a DOTA chelator for gallium-68 or lutetium-177 labeling.
Usually ships within 24 hours.